Bio-Path Holdings, Inc.
BPTH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | -0.04 | 0.05 |
| FCF Yield | -379.69% | -262.30% | -137.66% | -39.39% |
| EV / EBITDA | -0.17 | -0.22 | -0.06 | -0.18 |
| Quality | ||||
| ROIC | -1,787.18% | -1,118.07% | -95.62% | -40.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.07 | 0.72 | 1.09 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 8.32% | 23.73% | -51.44% | 8.88% |
| Safety | ||||
| Net Debt / EBITDA | 0.11 | 0.06 | 0.74 | 2.29 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.28 | 49.62 | 307.84 |
| Cash Conversion Cycle | -2,924.59 | 358.85 | -1,360.37 | -239.12 |